ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+16.76%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$234M
AUM Growth
+$234M
(-16%)
Cap. Flow
-$55.9M
Cap. Flow
% of AUM
-23.93%
Top 10 Holdings %
Top 10 Hldgs %
58.55%
Holding
51
New
5
Increased
8
Reduced
20
Closed
14
Top Buys
| 1 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
$5.94M |
| 2 |
Aligos Therapeutics
ALGS
|
$4.37M |
| 3 |
GH Research
GHRS
|
$3.26M |
| 4 |
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
|
$3.01M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$2.99M |
Top Sells
| 1 |
89bio
ETNB
|
$9.32M |
| 2 |
Curis
CRIS
|
$8.69M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$7.11M |
| 4 |
Mersana Therapeutics
MRSN
|
$5.79M |
| 5 |
Altimmune
ALT
|
$5.75M |
Sector Composition
| 1 | Healthcare | 93.7% |
| 2 | Financials | 6.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
VistaGen Therapeutics
VTGN
$102M
| $36.9M | 14.76% | 11,728,033 -567,734 | -5% | -$1.79M |
|
2
Celldex Therapeutics
CLDX
$1.47B
| $33M | 13.19% | 987,406 -30,118 | -3% | -$1.01M |
|
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $10.1M | 4.05% | 160,500 +47,339 | +42% | +$2.99M |
|
4
Arrowhead Research
ARWR
$3.05B
| $8.95M | 3.57% | 108,000 | – | – |
|
|
BLSA
5
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.88M | 3.55% | 843,122 | – | – |
|
6
Verastem
VSTM
$569M
| $8.22M | 3.28% | 2,018,433 -274,955 | -12% | -$1.12M |
|
|
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.89M | 3.15% | 1,250,000 -329,093 | -21% | -$2.08M |
|
8
Xenon Pharmaceuticals
XENE
$2.98B
| $7.77M | 3.11% | 417,409 +4,909 | +1% | +$91.4K |
|
|
SEEL
9
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $7.55M | 3.02% | 2,860,000 +1,140,188 | +66% | +$3.01M |
|
10
Kura Oncology
KURA
$686M
| $7.37M | 2.94% | 353,398 -183,422 | -34% | -$3.82M |
|
11
ESSA Pharma
EPIX
$11.4M
| $6.65M | 2.66% | 232,896 -54,104 | -19% | -$1.55M |
|
12
Clearside Biomedical
CLSD
$28.9M
| $6.41M | 2.56% | 1,316,268 -297,732 | -18% | -$1.45M |
|
13
Fulcrum Therapeutics
FULC
$351M
| $6.33M | 2.53% | 604,074 -18,426 | -3% | -$193K |
|
|
VINC
14
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $6.21M | 2.48% | 478,401 +84,401 | +21% | +$1.1M |
|
|
CYT
15
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $5.94M | 2.38% | +277,777 | New | +$5.94M |
|
|
JYAC
16
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.59M | 2.23% | 562,500 | – | – |
|
17
Athira Pharma
ATHA
$15.3M
| $4.37M | 1.75% | 427,060 +27,060 | +7% | +$277K |
|
|
18
Aligos Therapeutics
ALGS
$73.3M
| $4.37M | 1.75% | +214,254 | New | +$4.37M |
|
19
Cartesian Therapeutics
RNAC
$261M
| $4.28M | 1.71% | 1,024,668 +201,668 | +25% | +$843K |
|
|
CMRX
20
DELISTED
Chimerix, Inc.
CMRX
| $4.07M | 1.63% | 509,164 -198,666 | -28% | -$1.59M |
|
21
Orchestra BioMed
OBIO
$147M
| $4M | 1.6% | 392,500 | – | – |
|
22
Iovance Biotherapeutics
IOVA
$807M
| $3.89M | 1.55% | 149,495 +51,921 | +53% | +$1.35M |
|
|
AVDL
23
Avadel Pharmaceuticals
AVDL
$1.43B
| $3.78M | 1.51% | 561,011 -533,989 | -49% | -$3.59M |
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $3.54M | 1.41% | 206,126 -49,054 | -19% | -$842K |
|
25
EyePoint Pharmaceuticals
EYPT
$797M
| $3.33M | 1.33% | 369,863 -11,282 | -3% | -$101K |
|